1. Introduction {#sec1-ijms-20-01166}
===============

Autism spectrum disorders (ASD) include an array of conditions arising from neurodevelopmental defects during a crucial stage of brain formation characterized by deficits in communication ability, a paucity of social skills, repetitive behaviors, and narrow interests \[[@B1-ijms-20-01166]\]. Environmental factors and perinatal care may play a role in both ASD onset and severity, but often arises from a substantial genetic burden. Colvert et al. \[[@B2-ijms-20-01166]\] found heritability estimates of 56% to 95% among monozygotic twins, with additive genetic factors comprising a significant share of the burden.

Morphologically, the brains of individuals diagnosed with ASD contain abnormal neuronal growth patterns, including an overabundance of neurons and unusual dendritic spine profiles \[[@B3-ijms-20-01166],[@B4-ijms-20-01166]\]. Butler and others in 2005 \[[@B5-ijms-20-01166]\] suggested that common causal factors could contribute to both abnormal neuronal development, autism, and risk for malignancy in patients with autism, with macrocephaly and *PTEN* gene mutations seen in about one-fifth of affected individuals. *PTEN* is an important tumor-suppressor gene reported to play a role in tumor growth, hamartoma disorders (e.g., Cowden, Proteus, Bannayan--Riley--Ruvalcaba syndrome), overgrowth, and cancer \[[@B6-ijms-20-01166],[@B7-ijms-20-01166],[@B8-ijms-20-01166]\]. Several of these overgrowth-related disorders are also at risk of developing malignancy, particularly colorectal cancer.

The genetic architecture of ASD was extensively surveyed through genome-wide association studies (GWAS) and candidate gene approaches \[[@B9-ijms-20-01166],[@B10-ijms-20-01166],[@B11-ijms-20-01166]\]. Several pathways and mechanisms were proposed as mediating factors in the pathogenesis of disorders, although the causative agents of the vast majority of cases remain elusive. However, cross-talk between the canonical Wnt pathway, the Notch signaling cascade \[[@B12-ijms-20-01166]\], and other disturbed genes and pathways \[[@B13-ijms-20-01166],[@B14-ijms-20-01166]\] are believed to play a potential role and helpful in explaining an association with malignancy \[[@B15-ijms-20-01166],[@B16-ijms-20-01166]\]. Furthermore, MAPK and calcium signaling pathways, particularly overlapping calcium-PKC--Ras--Raf--MAPK/ERK processes are strongly associated with ASD. These pathways play a central role in a large range of biological processes and, when abnormal, may compromise biological output and contribute to neuropsychiatric disorders, cell growth, and malignancy \[[@B17-ijms-20-01166],[@B18-ijms-20-01166],[@B19-ijms-20-01166],[@B20-ijms-20-01166]\].

The *PTEN* gene product behaves as an inhibitor of the phosphoinositol 3-kinase/AKT pathway \[[@B21-ijms-20-01166]\]. Disturbances contribute to dysregulation in the pathway leading to excessive uncontrolled cell growth and malignancy. Butler et al. \[[@B5-ijms-20-01166]\] and Varga et al. \[[@B21-ijms-20-01166]\] previously reported elevated frequencies of heterozygous germline *PTEN* gene mutations in the ASD population, suggesting that mutations serve as a critical component of the shared cancer and ASD etiology requiring further research. Investigation into the connection of other genetic factors contributing to ASD and cancer could be of clinical utility. Individuals diagnosed with autism should be screened more frequently for cancers for which they may have a genetic susceptibility.

In the investigation herein, we utilized GeneAnalytics, which incorporates a computer-based bioinformatics pipeline developed by GeneCards, to identify and interrogate shared genes and their architecture between cancer and ASD. We explored influential shared pathways in overlapping genes which could represent potential therapeutic targets. We reviewed reports on the overlap between approximately 800 autism and over 3500 cancer-related genes utilizing this bioinformatics/pathway analysis program. GeneCards was used as an integrated, human genomic database to leverage information from 125 scholarly databases including genetic, transcriptomic, proteomic, functional, and clinical information to interrogate genomic-related data for our study \[[@B22-ijms-20-01166],[@B23-ijms-20-01166]\]. This novel study may supply information helpful to stimulate or address a potential medical or genetic conundrum and may provide a research-based foundation of common pathology in ASD and cancer.

2. Results {#sec2-ijms-20-01166}
==========

Using the VarElect program, autism and cancer genes were screened for overlapping units, according to phenotype category. VarElect identified 138 genes in common between the 792 reported known, susceptible, or clinically relevant genes for autism or ASD (17.4%), and 3.9% of approximately 3500 genes implicated in cancer. The 138 genes and their underlying biological functions were profiled by the commercially available GeneAnalytics program, previously validated in studies of random genes to test the interpretation power or relationship to the gene set under investigation \[[@B22-ijms-20-01166]\].

The GeneAnalytics output furnished a list of diseases highly associated with the combined cancer and autism gene set. The resulting high score matches (*p* \< 0.05) are presented, ranked by score, and categorized by disease type in [Table 1](#ijms-20-01166-t001){ref-type="table"}. The number of matched genes between the indicated disease and the autism and cancer gene set is included for context. Seven diseases were found to be significantly associated with the dataset, all of which pertain to cancer (see [Figure 1](#ijms-20-01166-f001){ref-type="fig"}). Three of the cancers are reproductive in nature (breast, prostate, and endometrial), while two are gastrointestinal (colorectal and pancreatic).

Super-pathways were likewise ranked and scored based on degree of association with the gene set. Top-scoring super-pathways are presented with matching rates in [Table 2](#ijms-20-01166-t002){ref-type="table"}, restricted to the top 30 of 371 significant entries (*p* \< 0.05). These included ubiquitous signaling super-pathways such as GPCR (score = 166, 54% match with gene set) and ERK (score = 146, 38% match). Numerous additional signaling super-pathways were found to be significantly associated with the combined gene set, including AKT, HGF development, CREB, cAMP-dependent PKA, fMLP, P70S6K, RET, TGF-β, PEDF induced, MTOR, and PI3K/AKT. Cancer-specific super-pathways, including "glioma" and "pathways in cancer", were also implicated at a statistically significant level (*p* \< 0.05) (see [Figure 2](#ijms-20-01166-f002){ref-type="fig"}).

Statistically significant Gene Ontology (GO) biological processes are presented in [Table 3](#ijms-20-01166-t003){ref-type="table"}, which are limited to the top 30 of 153 total high-scoring matches. The top three entries directly relate to the regulation of gene expression. These include "positive regulation of transcription, DNA-templated", "positive regulation of transcription from RNA polymerase II promoter", and "positive regulation of gene expression", which exhibited matching rates of 21%, 25%, and 15%, respectively, with the combined 138 overlapping gene set (see [Figure 3](#ijms-20-01166-f003){ref-type="fig"}).

The top 30 significant GO molecular functions, of 41 total significant entries, are delineated in [Table 4](#ijms-20-01166-t004){ref-type="table"}. Prominent entries include protein (score = 67, 83% match rate), enzyme (score = 43, 15% match rate), and β-catenin binding (score = 36, 8% match rate). Kinases and phosphatases were well represented in the analysis as well, with several obtaining high scores, including "protein kinase activity", "kinase activity", "TRK activity", "protein kinase binding", "protein tyrosine kinase activity", and "protein phosphatase binding" (see [Figure 4](#ijms-20-01166-f004){ref-type="fig"}).

The 30 top scoring phenotypes, of 145 significant matches, are outlined in [Table 5](#ijms-20-01166-t005){ref-type="table"}. Phenotypes reflect the importance of ASD and cancer-associated genes in growth and development-related processes (see [Figure 5](#ijms-20-01166-f005){ref-type="fig"}). The top phenotypes include "premature death" (score = 70, 28% match rate), "complete embryonic lethality during organogenesis" (score = 53, 20% match rate), and "decreased body size" (score = 51, 22% match rate).

3. Discussion {#sec3-ijms-20-01166}
=============

As anticipated in our examination of gene data and profiling, the diseases found most in common with the combined autism and malignancy gene set did pertain to cancer. Moreover, colorectal cancer accounted for 32% of overlapping genes, followed by breast and prostate cancer (see [Table 1](#ijms-20-01166-t001){ref-type="table"}). Two notable exceptions of our own cut-off criteria that may deserve further inspection include Alzheimer disease and amyotrophic lateral sclerosis (ALS), both of which approached but did not attain significance in their association with the gene set, achieving medium scores. Alzheimer disease and ALS are progressive neurodegenerative diseases \[[@B23-ijms-20-01166],[@B24-ijms-20-01166],[@B25-ijms-20-01166]\]. Alzheimer disease and ALS exhibited 11% and 8% overlap with the ASD and cancer gene set, which is a small, though not trivial connection. Enrichment of genes associated with neurodegenerative illnesses among the autism and cancer gene set may be indicative of shared disturbances in neurological growth and development which could contribute to the divergent morphology of autism, cancer, Alzheimer disease, and ALS.

Regarding diseases cited in [Table 1](#ijms-20-01166-t001){ref-type="table"}, one unusual observation was the lack of representation of brain and neurological diseases. Of the seven high-score matches and six selected borderline (medium-score) matches, only medulloblastoma qualified as a cancer of the brain and nervous system. Reproductive cancers (breast, prostate, and endometrial) and gastrointestinal cancers (colorectal, pancreatic, and hepatocellular carcinoma) were more prevalent. Notably, most of the cancers listed in [Table 1](#ijms-20-01166-t001){ref-type="table"} tend to be acquired diseases with a genetic diathesis (e.g., breast and prostate), as opposed to congenital diseases that arise early in development (medulloblastoma). It should also be noted that tumors of the ectoderm and endoderm were disproportionately represented relative to the mesoderm. This may reflect the tissue-specific nature of neural development in the onset of autism. Of note, ASD did not achieve statistical significance with the shared dataset, despite being a requisite for selection and receiving a relatively high-scoring entry. This may be a testament to the complexity of autism spectrum disorder. Even though the gene set was filtered by ASD connection, collectively, the combined genes were more diagnostic of cancer than ASD.

Overall, the highest-scoring super-pathways correlated more strongly with the autism and cancer combined gene set (as evidenced by the higher scores), compared to GO biological processes and GO molecular functions, which were not as strongly correlated, as reflected by their lower scores. The majority of super-pathways (see [Table 2](#ijms-20-01166-t002){ref-type="table"}) in the top 30 reported entries in the high-scoring category achieved a match rate of at least 20% with the gene set, indicating the relative importance of these super-pathways in the autism and cancer connection. The GeneAnalytics output of the highest scores strongly implicated the ERK signaling pathway in shared pathogenesis based on super-pathway analysis, with a score of 166 and a match rate of 54%, followed by the GPCR pathway at 38%. The MAPK/ERK signaling pathway occupies a key role in mitogen signaling and cell growth with survival \[[@B26-ijms-20-01166]\]. Disturbances in the ERK pathway can disrupt the cell cycle, leading to anomalous cell proliferation and malignant growth. Gene mutations or aberrant functioning in the pathway during early development could contribute to abnormal neuronal growth in ASD. Alterations in GPCR signaling could further contribute to the onset of ASD through aberrant cell signaling and neurotransmitter dysregulation, both of which might lead to changes in cognitive functioning characteristic of ASD.

For GO biological processes, the three highest-scoring entries pertain to the regulation of gene expression. The outcome of the analysis suggests that an important mechanism in the mutual pathology of autism and cancer may be attributed to variation in transcription factors and nongenic sequences and, hence, differences in the regulation and rate of gene expression. Processes involved in the growth, development, and death of cells were found to be highly associated with the gene set. Indeed, "positive regulation of apoptotic process", "apoptotic process", and "negative regulation of apoptotic process" were each flagged as biological processes significantly associated with the combined gene set, with scores of 39 (matching rate of 14%), 37 (18%), and 34 (15%), respectively. Additional growth and death biological processes were also found to be enriched in the gene set, including "heart development", "negative regulation of cell proliferation", "nervous system development", "positive regulation of cell proliferation", and the "canonical Wnt signaling pathway".

In terms of the GO molecular functions underlying cancer and autism pathology, the results strongly implicate "protein binding", which exhibited a score of 67, over 20 points larger than the second, less inclusive entry, "enzyme binding". Furthermore, 83% of the autism and cancer gene set with 115 out of 138 matched genes was associated with protein binding, suggesting that dysfunction in protein binding may play a significant role in the shared autism and cancer diathesis. In many respects, this paradigm is reflective of the pivotal role of protein binding in the diverse metabolic processes underlying growth and survival. There was a substantial disparity between the high matching rate of protein binding (83%) and that of enzyme binding specifically (15%). The remaining 68% of protein binding that is not explained by enzyme binding and activation by kinase pathways may be attributed to structural protein and signal--receptor binding. This may suggest that structural and signaling mechanisms are disproportionately involved in the shared pathology of cancer and autism as noted previously. MAPK and calcium signaling pathways in genes associated with autism are found in other disorders including cancer \[[@B19-ijms-20-01166]\]. Enzymes may play more of a peripheral role. Enzyme binding overlaps with kinase pathways, many of which are involved in enzyme activation. Kinase and phosphatase activities were also prevalent among the high-scoring entries. Ten of the 30 highest-scoring molecular functions pertain to kinase or phosphatase activity. Both protein binding and kinase activities align with "protein kinase binding".

The report also implicated β-catenin binding (score of 36; 8% matching rate); β-catenin functions as both a moderator of gene transcription and as an agent of intercellular adhesion \[[@B27-ijms-20-01166]\]. Overexpression of β-catenin, which is encoded by the *CTNNB1* gene, is well characterized as a candidate in the pathogenesis of numerous cancers, as well as heart disease (this may serve as a potential link to the high-scoring GO biological process of "heart development") (score = 44; match rate = 13%) \[[@B28-ijms-20-01166]\]. The relationship between β-catenin signaling and autism was reported, as β-catenin is dependent on the absence of Wnt \[[@B29-ijms-20-01166],[@B30-ijms-20-01166]\]. Its role in mediating cell adhesion and cellular development suggests it may be a candidate in the pathogenesis of both autism and cancer.

The two highest-scoring phenotypes, "premature death" and "complete embryonic lethality during organogenesis", reflect the delicacy of neurogenesis and embryonic development. It is likely that only certain combinations of mutations inherited from the autism and cancer gene set can be tolerated and that, at a certain genetic burden, dysfunction in pathways associated with these genes results in irretrievable failure to develop. Designated decreased body size and body weight may also reflect the vital importance of these genes in mediating development, early cell division and number, and the potential consequences of dysfunction.

Three functional pathways are potentially involved, which include genes and pathways for chromatin remodeling, (e.g., *CHD7*, *MECP2*, *DNMT3A*, and *PHF2*), Wnt (e.g., *CHD8*, *PAX5*, and *ATRX*), and other signaling super-pathways (e.g., GPCR, ERK, RET, and AKT) and mitochondrial dysfunction in ASD (e.g., Reference \[[@B30-ijms-20-01166]\]). Theoretically, drugs could be targeted to treat ASD. By developing a rank-ordered list of functional categories significantly associated with autism and cancer using GeneAnalytics pathways and profiling of shared autism and cancer genes, we identified potentially high-impact pathways and common mechanisms which may serve as therapeutic targets in future studies.

The interconnected relationship between autism and cancer invites further investigation in the pathogenesis of the two seemingly unrelated disorders, and it warrants a pharmacological basis of treatment. *PTEN* is an example of a shared gene for autism and cancer and the direct and indirect subject of several formally approved cancer therapeutics including cisplatin, erlotinib, everolimus, cetuximab, and estradiol. For example, cisplatin circumscribes DNA synthesis, activates caspase-3, and facilitates apoptosis, thus rescuing the function of mutant *PTEN* \[[@B31-ijms-20-01166]\]. Considering the role of cisplatin in complementing *PTEN* function, strategic application of the drug could potentially address the autism-associated symptoms arising from *PTEN* dysfunction. Another drug example is everolimus, which behaves as an inhibitor of the mammalian target of rapamycin, and it could impact cancer predisposition and possibly autism development in a manner similar to cisplatin \[[@B32-ijms-20-01166]\].

Although invasive drugs and treatments exist for many types of cancer, a drug is yet to be successfully developed to prevent the onset or progression of ASD symptomology. The unexpected shared etiology with overlapping genes between cancer and autism, particularly those involved in cell-signaling pathways such as MAPK and calcium signaling \[[@B19-ijms-20-01166]\], encourages cautious speculation that, as our knowledge of the staging and mechanisms of ASD improves and applied to animal model testing, the leverage of anti-cancer drugs at minimal dosages could be postulated. For example, the 16p11.2 chromosome deletion is one of the most common copy number variants linked to autism in humans and reportedly involves the *ERK1* gene and other related genes converging in the ERK/MAP kinase pathway. This pathway was the most recognized super-pathway found in our profiling analysis of autism and cancer genes (see [Table 2](#ijms-20-01166-t002){ref-type="table"}). Perturbations of this pathway can contribute to neuropsychiatric disorders, cell growth, and malignancy; therefore, treatment could lessen these manifestations. To investigate whether pharmacological approaches could be helpful, researchers used a 16p11.2 equivalent deletion mouse model with the *ERK1* gene deleted, and they found that pharmacological inhibitions of ERK signaling (i.e., RB1 and RB3 peptides) rescued cortical cytoarchitecture abnormalities and the abnormal behavioral phenotype associated with this deletion, providing evidence for a potential targeted therapeutic intervention for autism \[[@B33-ijms-20-01166]\]. Hypothetically, treatment could lessen the effects of autism when recognized early and during brain plasticity.

Furthermore, genetic analysis linked autism with mutations in tumor suppression genes and other cancer-associated genes and pathways reflected in our gene profiling analysis. Important candidate genes (e.g., *PTEN*, *NF1*, and *BRCA2*) are found meeting criteria clearly associated with predisposition to cancer such as colorectal, other gastrointestinal tumors, and breast reported in the top seven autism and cancer-associated diseases (see [Table 1](#ijms-20-01166-t001){ref-type="table"}). For example, mutations in the *PTEN* gene are linked to colorectal, thyroid, head, neck, prostate, skin, breast, and lung cancer and about 10% of children with autism have *PTEN* gene mutations, making this an important gene to target regarding therapeutic intervention for autism with predisposition to cancer. ASDs and cancer overlap extensively in signal transduction pathways as illustrated by our study, involving metabolic processes; these areas should be targeted by treatment strategies. Such insights may enable more accurate gene-informed cancer risk assessment for targeted therapeutic and medical management.

To date, there were a few preclinical models tested with anticancer medication on ASD symptoms. For example, Kilincaslan et al. \[[@B34-ijms-20-01166]\] reported the beneficial effects of everolimus on autism and attention-deficit hyperactivity disorder (ADHD) symptoms in a group of patients with tuberous sclerosis complex (TSC). This drug inhibits mTOR, one of the top 30 super-pathways identified with high scores when comparing shared autism and cancer genes. It is a treatment for TSC in which autism is a finding, along with renal angiomyolipomas and astrocytomas. The drug reduced tumor growth, decreased seizures, and improved autistic, ADHD, and depression symptoms. However, there is a paucity of studies on the effects of this drug on neuro-psychiatric symptoms, which merit further consideration. Treatment would be a new avenue to pursue and further explore, particularly in those with ASD, the involvement of shared autism and cancer-related genes.

4. Materials and Methods {#sec4-ijms-20-01166}
========================

Shared genetic architecture between cancer and ASD was examined firstly using VarElect, a sequence phenotyper affiliated with GeneAnalytics (Alameda, CA, USA) \[[@B35-ijms-20-01166],[@B36-ijms-20-01166]\]. A reported list of 792 clinically relevant, susceptible, or known genes for ASD, summarized previously by Butler et al. \[[@B37-ijms-20-01166]\], and over 3500 recognized cancer genes found in the GeneAnalytics databases were entered into the VarElect phenotyper program to identify overlapping genes.

The ASD genes were filtered by their association with the query "cancer" and limited to those with established pathways. Based on the above parameters, VarElect produced 138 genes with known connections to both cancer and ASD. The refined list of 138 genes was then entered into GeneAnalytics, a gene set analytical tool which uses GeneCards, an integrated genomic database, to parse genes and their relationships, as previously reported \[[@B22-ijms-20-01166],[@B38-ijms-20-01166],[@B39-ijms-20-01166],[@B40-ijms-20-01166]\].

The GeneAnalytics program produces a report containing seven categories: diseases, pathways, tissues and cells, phenotypes, Gene Ontology (GO) molecular functions, GO biological processes, and compounds related to the query of interest (i.e., cancer and ASD gene). Each entry in these functional categories was sorted with the GeneAnalytics proprietary matching and scoring algorithm following protocols published previously in the study of psychiatric, behavior, and obesity-related genes by our research group \[[@B22-ijms-20-01166],[@B39-ijms-20-01166],[@B40-ijms-20-01166]\]. Only those genes with the highest calculated scores were further analyzed for each of the seven GeneAnalytics categories. In addition to scoring fields based on their relevance to the gene set, fields were subdivided into three categories, "high-score matches", "medium-score matches", and "low-score matches". High-score matches exhibited a corrected *p*-value of less than 0.05, while medium-score matches exhibited a corrected *p*-value between 0.05 and 0.1. For the purposes of this investigation, medium- and low-score matches were excluded from the results. The reporting of high-score matches was restricted to the top 30 entries, in instances where more than 30 were found to be significant (*p* \< 0.05). Corrections were made based on multiple testing (Bonferroni correction).
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ijms-20-01166-t001_Table 1

###### 

Profiling of high scores in overlapping genes for autism and cancer-associated diseases.

  Score   Disease                   Disease Categories                                                                                Number of Matched Genes (% of 138 Overlapping Genes)
  ------- ------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------
  33.84   Colorectal cancer         Gastrointestinal diseases, genetic diseases, rare diseases, cancer diseases                       44 (32%)
  30.70   Breast cancer             Reproductive diseases, genetic diseases, rare diseases, cancer diseases                           39 (28%)
  24.13   Prostate cancer           Reproductive diseases, genetic diseases, rare diseases, cancer diseases                           31 (22%)
  19.01   Lung cancer               Respiratory diseases, genetic diseases, cancer diseases                                           25 (18%)
  18.43   Endometrial cancer        Reproductive diseases, genetic diseases, rare diseases, cancer diseases                           19 (14%)
  13.94   Leukemia, acute myeloid   Immune diseases, blood diseases, genetic diseases, rare diseases, cancer diseases                 15 (11%)
  13.64   Pancreatic cancer         Gastrointestinal diseases, endocrine diseases, genetic diseases, rare diseases, cancer diseases   15 (11%)

ijms-20-01166-t002_Table 2

###### 

Profiling of high scores in overlapping genes for autism and cancer-associated super-pathways.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Score    Super-Pathways                                                                                    Number of Total Genes   Number of Super-Pathway Matched Genes   \% of 138 Overlapping Genes
  -------- ------------------------------------------------------------------------------------------------- ----------------------- --------------------------------------- -----------------------------
  166.10   Elk-related tyrosine kinase (ERK) signaling                                                       1177                    74                                      54%

  145.73   glioma                                                                                            313                     44                                      32%

  131.74   G-protein coupled receptor (GPCR) pathway                                                         708                     53                                      38%

  122.48   Pathways in cancer                                                                                395                     42                                      30%

  116.32   Signaling by GPCR                                                                                 2601                    80                                      58%

  113.29   Phospholipase-C pathway                                                                           498                     43                                      31%

  98.91    Human immune-deficiency virus (HIV) life cycle                                                    865                     48                                      35%

  97.32    NANOG in mammalian embryonic stem cell pluripotency                                               533                     40                                      29%

  95.18    Apoptotic pathways in synovial fibroblasts                                                        725                     44                                      32%

  95.13    AKT murine thymoma viral oncogene homolog (AKT) signaling                                         681                     43                                      31%

  94.06    Development HGF signaling                                                                         234                     30                                      22%

  90.05    CAMP response element-binding protein (CREB) pathway                                              528                     38                                      28%

  81.54    Integrated breast cancer pathway                                                                  154                     24                                      17%

  81.30    Proteoglycans in cancer                                                                           203                     26                                      19%

  80.40    Nuclear factor of activated (NFAT)\                                                               326                     30                                      22%
           T cells and cardiac hypertrophy                                                                                                                                   

  78.97    Integrin pathway                                                                                  568                     36                                      26%

  78.26    Development of vascular endothelial growth factor (VEGF) signaling via VEGFR2, generic cascades   147                     23                                      17%

  77.70    Activation of cyclic adenosine monophosphate (CAMP)-dependent protein kinase A (PKA)              628                     37                                      27%

  77.43    Formyl peptide receptor (FMLP) pathway                                                            317                     29                                      21%

  77.00    P70S6K signaling                                                                                  390                     31                                      22%

  74.95    Rearranged during transfection (RET) signaling                                                    974                     43                                      31%

  72.42    Transforming growth factor (TGF)-beta pathway                                                     652                     36                                      26%

  72.03    Glioblastoma multiforme                                                                           111                     20                                      14%

  71.00    Pigment epithelium-deprived factor (PEDF) induced signaling                                       721                     37                                      27%

  70.30    P21-activated kinase (PAK) pathway                                                                682                     36                                      26%

  69.39    Endometrial cancer                                                                                122                     20                                      14%

  67.08    Mechanistic target of rapamycin (MTOR) signaling pathway (KEGG)                                   209                     23                                      17%

  66.63    PI3K/AKT signaling pathway                                                                        342                     27                                      20%

  66.33    Developmental biology                                                                             1079                    42                                      30%

  65.44    Focal adhesion                                                                                    283                     25                                      18%
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ijms-20-01166-t003_Table 3

###### 

Profiling of high scores in overlapping genes for autism and cancer-associated Gene Ontology (GO) biological processes.

  Score   GO Biological Processes                                                                     Number of Total Genes   Number of Matched Genes   \% of 138 Overlapping Genes
  ------- ------------------------------------------------------------------------------------------- ----------------------- ------------------------- -----------------------------
  53.00   Positive regulation of transcription, DNA-templated                                         596                     29                        21%
  46.66   Positive regulation of transcription from RNA polymerase II promoter                        1016                    34                        25%
  44.49   Positive regulation of gene expression                                                      346                     21                        15%
  44.10   Heart development                                                                           232                     18                        13%
  42.44   Negative regulation of cell proliferation                                                   419                     22                        16%
  41.44   Nervous system development                                                                  535                     24                        17%
  39.38   Intracellular signal transduction                                                           467                     22                        16%
  39.37   Protein phosphorylation                                                                     629                     25                        18%
  39.02   Positive regulation of apoptotic process                                                    330                     19                        14%
  37.45   Positive regulation of protein phosphorylation                                              155                     14                        10%
  36.52   Apoptotic process                                                                           690                     25                        18%
  36.16   Positive regulation of sequence-specific DNA-binding transcription factor activity          105                     12                        9%
  34.58   Positive regulation of cell proliferation                                                   500                     21                        15%
  34.22   Negative regulation of apoptotic process                                                    507                     21                        15%
  33.45   Phosphorylation                                                                             700                     24                        17%
  31.65   Canonical Wnt signaling pathway                                                             80                      10                        7%
  31.62   Cell adhesion                                                                               620                     22                        16%
  31.02   Phosphatidylinositol-mediated signaling                                                     112                     11                        8%
  30.96   Signal transduction                                                                         2032                    40                        29%
  29.94   Response to drug                                                                            323                     16                        12%
  29.83   Thymus development                                                                          44                      8                         6%
  29.33   Visual learning                                                                             46                      8                         6%
  28.92   Extracellular matrix organization                                                           203                     13                        9%
  28.09   Protein autophosphorylation                                                                 173                     12                        9%
  27.55   Negative regulation of transcription from RNA polymerase II promoter                        724                     22                        16%
  27.40   Cell-cycle arrest                                                                           143                     11                        8%
  27.05   Regulation of phosphatidylinositol 3-kinase signaling                                       82                      9                         7%
  26.20   Substrate adhesion-dependent cell spreading                                                 39                      7                         5%
  25.00   Negative regulation of cysteine-type endopeptidase activity involved in apoptotic process   68                      8                         6%
  24.79   Peptidyl-tyrosine phosphorylation                                                           171                     11                        8%

ijms-20-01166-t004_Table 4

###### 

Profiling of high scores in overlapping genes for autism and cancer-associated GO molecular functions.

  Score   GO Molecular Functions                                                                                          Number of Total Genes   Number of Matched Genes   \% of 138 Overlapping Genes
  ------- --------------------------------------------------------------------------------------------------------------- ----------------------- ------------------------- -----------------------------
  66.97   Protein binding                                                                                                 9013                    115                       83%
  43.40   Enzyme binding                                                                                                  360                     21                        15%
  36.09   β-Catenin binding                                                                                               80                      11                        8%
  35.87   Protein kinase activity                                                                                         530                     22                        16%
  30.98   Kinase activity                                                                                                 698                     23                        17%
  30.91   Transcription factor binding                                                                                    308                     16                        12%
  27.55   Transmembrane receptor protein tyrosine kinase activity                                                         54                      8                         6%
  27.38   Identical protein binding                                                                                       797                     23                        17%
  25.54   Protein kinase binding                                                                                          402                     16                        12%
  25.40   Protein tyrosine kinase activity                                                                                164                     11                        8%
  23.70   Transcription regulatory region DNA binding                                                                     229                     12                        9%
  21.10   Phosphatidylinositol-4,5-bisphosphate 3-kinase activity                                                         66                      7                         5%
  20.68   Protein phosphatase binding                                                                                     69                      7                         5%
  20.58   RNA polymerase II Core promoter proximal region sequence-specific DNA binding                                   336                     13                        9%
  20.43   Protein C-terminus binding                                                                                      185                     10                        7%
  19.66   Ubiquitin protein ligase binding                                                                                299                     12                        9%
  18.88   Transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding   260                     11                        8%
  17.81   Repressing transcription factor binding                                                                         34                      5                         4%
  17.69   Protein homodimerization activity                                                                               758                     18                        13%
  17.69   Chromatin binding                                                                                               404                     13                        9%
  17.45   Cell adhesion molecule binding                                                                                  63                      6                         4%
  17.27   C--X3--C chemokine binding                                                                                      5                       3                         2%
  16.82   Protein heterodimerization activity                                                                             495                     14                        10%
  16.48   Nitric-oxide synthase regulator activity                                                                        6                       3                         2%
  16.19   Androgen receptor binding                                                                                       43                      5                         4%
  15.95   Protein domain specific binding                                                                                 264                     10                        7%
  15.57   Transferase activity                                                                                            1759                    28                        20%
  15.54   Receptor binding                                                                                                398                     12                        9%
  15.50   Nuclear hormone receptor binding                                                                                23                      4                         3%
  15.28   Transcription factor activity, sequence-specific DNA binding                                                    1029                    20                        14%
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###### 

Profiling of high scores in overlapping genes for autism and cancer-associated phenotypes.

  Score   Phenotypes                                                   Number of Total Genes   Number of Matched Genes   \% of 138 Overlapping Genes
  ------- ------------------------------------------------------------ ----------------------- ------------------------- -----------------------------
  70.49   Premature death                                              832                     39                        28%
  53.00   Complete embryonic lethality during organogenesis            540                     28                        20%
  51.00   Decreased body size                                          742                     31                        22%
  46.85   Decreased body weight                                        1144                    36                        26%
  37.37   Decreased embryo size                                        450                     21                        15%
  36.64   Decreased thymocyte number                                   102                     12                        9%
  34.08   Embryonic growth retardation                                 404                     19                        14%
  33.98   Increased leukocyte cell number                              120                     12                        9%
  33.98   Enlarged heart                                               120                     12                        9%
  33.25   Abnormal heart development                                   158                     13                        9%
  33.05   Decreased B-cell number                                      196                     14                        10%
  29.78   Partial embryonic lethality during organogenesis             234                     14                        10%
  29.60   Partial postnatal lethality                                  546                     20                        14%
  29.50   Increased tumor incidence                                    124                     11                        8%
  28.15   Enlarged spleen                                              256                     14                        10%
  27.97   Abnormal sensory neuron innervation pattern                  52                      8                         6%
  27.76   Abnormal rostral--caudal axis patterning                     53                      8                         6%
  27.60   Complete prenatal lethality                                  264                     14                        10%
  27.18   Partial perinatal lethality                                  225                     13                        9%
  27.13   Hyperactivity                                                271                     14                        10%
  27.09   Abnormal blood vessel morphology                             146                     11                        8%
  27.04   Increased mammary adenocarcinoma incidence                   20                      6                         4%
  26.94   Complete lethality throughout fetal growth and development   186                     12                        9%
  26.90   Abnormal response/metabolism to endogenous compounds         83                      9                         7%
  26.76   Complete postnatal lethality                                 378                     16                        12%
  25.78   Abnormal B-cell differentiation                              91                      9                         7%
  25.38   Abnormal definitive hematopoiesis                            94                      9                         7%
  24.21   Abnormal heart morphology                                    178                     11                        8%
  24.05   Decreased sensory neuron number                              14                      5                         4%
  23.89   Partial prenatal lethality                                   274                     13                        9%
